The Lynx Group

January 2013, Vol 4, No 1

Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.
Read Article

Vienna, Austria—Several studies presented at the 2012 European Society for Medical Oncology Congress offered a look into what many believe will lead to the application of genome-based biomarker information into clinical use based on the concept of personalized medicine, although not all of the results were unconditionally encouraging.
Read Article

A recent study compared the benefit of abiraterone acetate (Zytiga) with prednisone versus placebo plus prednisone for patients with mCRPC before chemotherapy (Ryan CJ, et al. N Engl J Med. 2013;368:138-148).
Read Article

Ensuring access to clinical trials to all patients is important not only to ensure equal access to care but also to make sure that clinical trial results can be generalized to all patients in the real-world setting. For the first time, a team of British researchers has recently investigated this question, revealing important implications for healthcare stakeholders (Noor AM, et al. J Clin Oncol. 2012;31:224-230).
Read Article

Boston, MA—Researchers believe they are closing in on a better way to identify breast cancers that are particularly dangerous and therefore require more aggressive therapy.
Read Article

For the prevention of recurrent venous thromboembolism (VTE), rivaroxaban (Xarelto) appears to be more cost-effective than warfarin (Coumadin), an independent analysis undertaken by the University of Pittsburgh School of Medicine showed.
Read Article

Atlanta, GA—Support for the oral immunomodulatory agent pomalidomide for the treatment of multiple myeloma took a giant step forward when new data from the phase 3 MM-003 trial showed a survival advantage in patients with advanced disease.
Read Article

Atlanta, GA—Promising preliminary results for oprozomib (ONX 0912), an orally available structural analogue of carfilzomib (Kyprolis), were presented at the 2012 American Society of Hematology meeting.
Read Article

Atlanta, GA—MLN9708, an investigational oral proteasome inhibitor, produced impressive results in a phase 1/2 clinical trial of treatment-naïve patients with multiple myeloma that was featured in a press briefing at the 2012 American Society of Hematology (ASH) meeting.
Read Article

A study using real-world data for patients with tumor lysis syndrome (TLS) showed that treatment with rasburicase (Elitek) was associated with significantly greater reductions in uric acid, length of hospital stay, and total hospitalization costs per patient compared with allopurinol (Zyloprim).
Read Article

Page 2 of 4

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: